Integrilin

Active Ingredient:: Eptifibatide
Origin:: EU

Integrilin (Eptifibatide)

Q: What is Integrilin used for?

Integrilin, whose active ingredient is eptifibatide, is used as an antiplatelet agent in acute coronary syndrome and during percutaneous coronary intervention. It helps prevent platelet aggregation and thrombus formation in patients at high risk of cardiac events.

Q: How does eptifibatide work?

Eptifibatide reversibly binds to the glycoprotein IIb/IIIa receptors on platelets, blocking the binding site for fibrinogen. This inhibition stops the final step of platelet aggregation, reducing clot formation during acute coronary events and interventional procedures.

Q: What is the usual dose of Integrilin?

The dosing regimen for Integrilin is determined by the prescribing clinician based on the patient’s clinical condition, weight, and renal function. Healthcare professionals follow established guidelines and adjust the infusion rate as needed.

Q: Is Integrilin safe in pregnancy or breastfeeding?

The safety of eptifibatide in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

Q: How do I order Integrilin from GNH India?

To request Integrilin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Q: How does Integrilin compare with other antiplatelet agents?

Integrilin is a glycoprotein IIb/IIIa inhibitor, offering rapid and potent platelet inhibition compared with oral agents such as clopidogrel or ticagrelor, which act earlier in the platelet activation cascade. Its reversible binding allows for relatively quick cessation of effect after infusion stops, which can be advantageous in procedural settings.

Q: What are the storage requirements for Integrilin?

Integrilin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging to maintain stability until it is prepared for intravenous administration.

Q: How is Integrilin administered?

Integrilin is supplied as a sterile injection for intravenous use. It is typically given as an initial bolus followed by a continuous infusion, administered by a qualified healthcare professional in a monitored clinical setting such as a cardiac catheterization lab or intensive care unit.

Q: What are the most serious risks associated with Integrilin?

The most serious risks include severe bleeding, profound thrombocytopenia, and rare hypersensitivity reactions. Clinicians must monitor patients closely for signs of uncontrolled hemorrhage, platelet count drops, and any allergic manifestations during and after the infusion.

Q: Who should not use Integrilin?

Integrilin is contraindicated in patients with active major bleeding, known hypersensitivity to eptifibatide or any component of the formulation, and in those who have had recent intracranial hemorrhage. Caution is also advised for patients with severe renal impairment.

Eptifibatide, the active ingredient in Integrilin, is a glycoprotein IIb/IIIa inhibitor presented as an injection for intravenous use. It is employed in the management of acute coronary syndrome and during percutaneous coronary intervention to prevent platelet aggregation in at‑risk patients.

GNH India supplies Integrilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Glaxosmithkline (Ireland) Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Integrilin (eptifibatide) is used within the antiplatelet therapy pathway for cardiovascular emergencies.
Acute coronary syndrome: reduces the incidence of ischemic complications during acute management.
Unstable angina/NSTEMI: provides rapid platelet inhibition to improve coronary blood flow.
Percutaneous coronary intervention: prevents thrombotic occlusion of the treated vessel during and after the procedure.

How It Works

Eptifibatide is a reversible antagonist of platelet glycoprotein IIb/IIIa receptors. By binding to these receptors, it blocks the final common pathway for fibrinogen cross‑linking, thereby inhibiting platelet aggregation and thrombus formation during acute coronary events and interventional procedures.

Side Effects

Eptifibatide may be associated with a range of adverse reactions.

Common Side Effects

Bleeding at the injection site
Minor bruising or hematoma
Mild thrombocytopenia
Nausea or vomiting
Transient hypotension

Serious or Rare Side Effects

Severe or uncontrolled bleeding
Thrombocytopenia with platelet count <50,000/µL
Acute coronary thrombosis despite therapy
Anaphylactic or hypersensitivity reactions
Hemolytic anemia

Precautions & Warnings

When using Integrilin, clinicians should consider several safety measures.
Renal impairment: adjust infusion rate and monitor renal function.
Recent surgery or trauma: evaluate bleeding risk before initiation.
Concurrent anticoagulants: assess cumulative anticoagulation effect.
History of bleeding disorders: use with caution and monitor closely.
Pregnancy and lactation: safety not established; weigh benefits against risks.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Eptifibatide can interact with other agents that affect hemostasis.

Major Interactions (Avoid)

Concurrent use of other glycoprotein IIb/IIIa inhibitors
High‑dose unfractionated heparin
Direct thrombin inhibitors (e.g., bivalirudin)

Moderate Interactions (Monitor Closely)

Low‑molecular‑weight heparins
Oral anticoagulants (warfarin, DOACs)
Antiplatelet agents such as aspirin or clopidogrel
Non‑steroidal anti‑inflammatory drugs (NSAIDs)
Fibrinolytic therapy

Frequently Asked Questions

Integrilin, whose active ingredient is eptifibatide, is used as an antiplatelet agent in acute coronary syndrome and during percutaneous coronary intervention. It helps prevent platelet aggregation and thrombus formation in patients at high risk of cardiac events.

Eptifibatide reversibly binds to the glycoprotein IIb/IIIa receptors on platelets, blocking the binding site for fibrinogen. This inhibition stops the final step of platelet aggregation, reducing clot formation during acute coronary events and interventional procedures.

The dosing regimen for Integrilin is determined by the prescribing clinician based on the patient’s clinical condition, weight, and renal function. Healthcare professionals follow established guidelines and adjust the infusion rate as needed.

The safety of eptifibatide in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Integrilin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Integrilin is a glycoprotein IIb/IIIa inhibitor, offering rapid and potent platelet inhibition compared with oral agents such as clopidogrel or ticagrelor, which act earlier in the platelet activation cascade. Its reversible binding allows for relatively quick cessation of effect after infusion stops, which can be advantageous in procedural settings.

Integrilin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging to maintain stability until it is prepared for intravenous administration.

Integrilin is supplied as a sterile injection for intravenous use. It is typically given as an initial bolus followed by a continuous infusion, administered by a qualified healthcare professional in a monitored clinical setting such as a cardiac catheterization lab or intensive care unit.

The most serious risks include severe bleeding, profound thrombocytopenia, and rare hypersensitivity reactions. Clinicians must monitor patients closely for signs of uncontrolled hemorrhage, platelet count drops, and any allergic manifestations during and after the infusion.

Integrilin is contraindicated in patients with active major bleeding, known hypersensitivity to eptifibatide or any component of the formulation, and in those who have had recent intracranial hemorrhage. Caution is also advised for patients with severe renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.